Why Is Repare Therapeutics Stock Trading Lower On Friday?
Why Is Repare Therapeutics Stock Trading Lower On Friday?
The most common adverse event was anemia (26.9%, Grade 3).On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
週四，Repare Therapeutics Inc（納斯達克：RPTX）公佈了其MYTHIC 1期婦科擴展試驗的數據，評估了lunresertib和camonsertib（Lunre+Camo）聯合治療有lunre敏感性生物標誌物的子宮內膜癌和鉑金抗藥性卵巢癌（PROC）。
As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial.
截至2023年11月14日的數據截止日期，共有51名可評估患者被納入MYTHIC試驗的婦科癌症擴展隊列。
Across all tumor types treated at the optimized RP2D (n=67), Lunre+Camo therapy showed a favorable and differentiated tolerability profile compared to current and emerging therapies.
在優化的RP2D下治療的所有腫瘤類型中（n=67），Lunre+Camo治療顯示出與當前和新興療法相比，良好且有區別的耐受性特徵。
The most common adverse event was anemia (26.9%, Grade 3).
最常見的不良事件是貧血（26.9％，3級）。
Key Cohort Clinical Findings
關鍵隊列臨床發現
Key efficacy outcomes from 27 evaluable patients with endometrial cancer show:
27名可評估的子宮內膜癌患者的關鍵療效結果顯示：
- Overall response rate was 25.9% (confirmed ORR in 5 out of 7 patients).
- Clinical benefit was observed in 48.1% of patients, with responses frequently occurring after 12 weeks or more.
- At the 24-week landmark analysis, nearly half of patients experienced durable clinical benefit (24-week PFS [PFS24w] = 43%.
- 總體反應率爲25.9%（在7名患者中確認的ORR爲5名）。
- 48.1%的患者觀察到臨床益處，反應通常在12周或更長時間後發生。
- 在24周的里程碑分析中，近一半的患者經歷了持久的臨床獲益（24周無進展生存期[PFS24w] = 43%）。
Key efficacy outcomes in 24 evaluable Platinum-Resistant Ovarian Cancer patients show:
在24例可評估的鉑金耐藥性卵巢癌患者中，關鍵療效結果顯示：
- Overall response rate was 37.5% (confirmed ORR in 4 out of 9 patients).
- Clinical benefit was observed in 79% of patients.
- PFS at the 24-week landmark analysis was PFS24w = 45%.
- 總體反應率爲37.5%（在9名患者中確認的ORR爲4名）。
- 在79%的患者中觀察到臨床獲益。
- 在24周的里程碑分析中，PFS爲PFS24w = 45%。
Repare has consulted with the FDA and the European Medicines Agency, who have guided the company's registrational development plans for Lunre+Camo in gynecologic tumors.
Repare已與FDA和歐洲藥品管理局進行諮詢，這些機構指導公司在婦科腫瘤領域的註冊開發計劃。
Repare plans to provide the final Phase 3 trial protocols for regulatory clearance imminently and intends to start the first Phase 3 Lunre+Camo trial in endometrial cancer in the second half of 2025.
Repare計劃儘快提供最終的第三期臨床試驗方案以獲得監管批准， 並打算在2025年下半年開始首次的第三期Lunre+Camo試驗，針對子宮內膜癌。
Additionally, the company expects to initiate a small contribution of components trial in up to 40 patients with endometrial cancer in the first quarter of 2025.
此外，公司預計將在2025年第一季度啓動一個針對多達40名子宮內膜癌患者的小規模元件試驗。
Price Action: RPTX stock is down 52.4% at $1.89 at last check Friday.
價格走勢：RPTX 股票在最後一次檢查時下跌了52.4%，目前價格爲1.89美元。
- CF Industries Carbon Capture Credits EBITDA Potential Could Be As High As $50 Million: Analyst
- CF Industries碳捕獲信貸的息稅折舊攤銷前利潤潛力可能高達5000萬美元：分析師
Photo via Shutterstock.
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
